![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Comment |
|---|---|
| Title: | Can MQ232 guide to novel options for treatment of ADPKD? |
| Creators: |
Klussmann, Enno  ORCID: https://orcid.org/0000-0003-4004-5003
|
| Abstract: | Wang et al. showcase a green mamba-derived compound, MQ232, which interferes with cyst growth in a mouse model of autosomal dominant polycystic kidney disease, similar to the only approved drug for autosomal dominant polycystic kidney disease treatment, tolvaptan. However, the authors reveal cyclic adenosine monophosphate–dependent and -independent components in MQ232’s mode of action and gender differences in efficacy. Therefore, MQ232 may pave the way to novel treatment options for autosomal dominant polycystic kidney disease. |
| Keywords: | Animal Disease Models, Animals, Autosomal Dominant Polycystic Kidney, Cyclic AMP, Tolvaptan, Animals, Mice |
| Source: | Kidney International |
| ISSN: | 0085-2538 |
| Publisher: | Elsevier |
| Volume: | 110 |
| Number: | 3 |
| Page Range: | 522-525 |
| Date: | September 2026 |
| Official Publication: | https://doi.org/10.1016/j.kint.2026.06.020 |
Repository Staff Only: item control page
